Sun Pharma completes Taro merger
Combined entity is better positioned to compete in increasingly competitive generics industry
Combined entity is better positioned to compete in increasingly competitive generics industry
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Subscribe To Our Newsletter & Stay Updated